跳转至内容
Merck
CN
所有图片(1)

主要文件

MAB1553

Sigma-Aldrich

抗肌联蛋白抗体，克隆9B9

culture supernatant, clone 9B9, Chemicon®

别名:

Anti-CMD1G, Anti-CMPD4, Anti-EOMFC, Anti-HMERF, Anti-LGMD2J, Anti-LGMDR10, Anti-MYLK5, Anti-SALMY, Anti-TMD

登录查看公司和协议定价
所有图片(1)

About This Item

UNSPSC代码:
12352203
eCl@ss:
32160702
NACRES:
NA.41

生物来源

mouse

质量水平

100

抗体形式

culture supernatant

抗体产品类型

primary antibodies

克隆

9B9, monoclonal

种属反应性

human

制造商/商品名称

Chemicon®

技术

immunohistochemistry: suitable
western blot: suitable

同位素/亚型

IgG1

NCBI登记号

NM_003319.3
NM_133378.3
NM_133379.2
NM_133432.2
NM_133437.2

UniProt登记号

Q8WZ42

运输

dry ice

靶向翻译后修饰

unmodified

基因信息

human ... TTN(7273)

特异性

人骨骼肌肌联蛋白。

免疫原

电泳纯化的人骨骼肌肌联蛋白。

应用

免疫化学：未稀释至1：10

蛋白质印迹：1:10-1:20

最佳稀释度必须由最终用户确定。
研究子类别
细胞骨架
研究类别
细胞结构
该抗肌联蛋白抗体克隆9B9已验证可用于 WB、IH中的肌联蛋白检测。

外形

液体。含0.1％叠氮化钠。

储存及稳定性

以未稀释的等分试样在-20°C下冷冻保存长达12 个月。应避免反复冻/融循环。

法律信息

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

免责声明

除非我们的产品目录或产品附带的其他公司文档另有说明，否则我们的产品仅供研究使用，不得用于任何其他目的，包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或任何类型的消费或应用于人类或动物。

未找到合适的产品？  

试试我们的产品选型工具.

储存分类代码

12 - Non Combustible Liquids

WGK

nwg

闪点(°F)

Not applicable

闪点(°C)

Not applicable

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Rafael De Cid et al.
Neurology, 85(24), 2126-2135 (2015-11-20)
To identify the genetic defects present in 3 families with muscular dystrophy, contractures, and calpain 3 deficiency. We performed targeted exome sequencing on one patient presenting a deficiency in calpain 3 on Western blot but for which mutations in the
Hong-Kee Tan et al.
Stem cells translational medicine, 3(5), 586-598 (2014-03-22)
Induced pluripotent stem cells (iPSCs) derived from somatic cells of patients can be a good model for studying human diseases and for future therapeutic regenerative medicine. Current initiatives to establish human iPSC (hiPSC) banking face challenges in recruiting large numbers
Stoyan Petkov et al.
Cells, 9(11) (2020-11-11)
Induced pluripotent stem cells (iPSCs) hold enormous potential for the development of cell-based therapies; however, the safety and efficacy of potential iPSC-based treatments need to be verified in relevant animal disease models before their application in the clinic. Here, we
Michael Stauske et al.
Cells, 9(6) (2020-06-04)
Non-human primates (NHP) are important surrogate models for late preclinical development of advanced therapy medicinal products (ATMPs), including induced pluripotent stem cell (iPSC)-based therapies, which are also under development for heart failure repair. For effective heart repair by remuscularization, large

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门